Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19
- PMID: 33555810
- DOI: 10.1097/EDE.0000000000001250
Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19
Conflict of interest statement
The authors report no conflicts of interest.
Comment on
-
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17. Circ Res. 2020. PMID: 32302265 Free PMC article.
References
-
- Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671–1681.
-
- Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492–499.
-
- Suissa S, Ernst P. β-Blockers for COPD inpatients. Thorax. 2012;67:936–937.
-
- Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
